Celea Therapeutics, Inc. has dosed the first patient in its global Phase 3 SURPASS-IPF trial, which is evaluating deupirfenidone 825 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE